Vertex cancels CF trials in France

French cystic fibrosis patients may not receive access to treatments under development by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) after the company canceled French sites for three planned Phase III trials slated to evaluate combinations of the biotech's CF transmembrane conductance regulators (CFTRs).

Although Vertex did confirm the cancellations to BioCentury, the company declined to offer an explanation. Three French CF

Read the full 584 word article

User Sign In